以表皮生长因子受体为靶点的肿瘤分子靶向治疗

Epidermal growth factor receptor targeted molecularly therapies of cancers

表皮生长因子受体（EGFR）是多种肿瘤发展和生长过程的重要因素，EGFR信号转导系统在肿瘤细胞的增殖、血管形成、转移以及细胞凋亡抵抗中起关键作用。最近，抗EGFR单克隆抗体和EGFR．酪氨酸激酶抑制剂已经作为治疗EGFR阳性肿瘤的新方法进行临床应用，并且在对晚期和化疗耐药肿瘤的临床试验中表现出活性。本文综述了3类针对EGFR的靶分子药物。

Epidermal growth factor receptor （EGFR） has been known to be a significant factor in the development and growth of many types of cancers. It is now accepted that the EGFR signal transduction net work plays an important role in multiple tumorigenic processes, contributing to cancercell proliferation, angiogenesis, and metastasis, as well as protection from apoptosis. Recently, EGFR monoclonal antibodies（McAb） and epidermal growth factor receptor-tyrosine kinase （EGFR-TK） inhibitors have been validated as new treatment approach for those EGFR-positive cancers and have shown activity aginst advanced, chemofractory cancers in clinical trials. This article focuses on three EGFR targeted molecularly therapies of cancers.